Company intelligence / Profile preview
CellSight Technologies
San Francisco, California, United Statescellsighttech.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
CellSight Technologies has developed [18F]F-AraG (VisAcT), a PET imaging agent that preferentially accumulates in activated T cells, enabling their tracking throughout the body. Recent studies have shown its ability to predict survival in immunotherapy-treated non-small cell lung cancer patients and reveal long-term immune system activation following COVID-19 infection.
- Therapeutic areas
- OncologyNeurologyInfectious Diseases
- Modalities
- PET imaging agentsdiagnostic radiopharmaceuticalssmall molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
UCSFUC DavisDana FarberStanford UniversityKyoto University
Beyond the preview
Go deeper on CellSight Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CellSight Technologies.